Small RNA signatures of the anterior cruciate ligament from patients with knee joint osteoarthritis

Yalda A. Kharaz^{1,2}, Yongxiang Fang³, Tim Welting⁴, Mandy Peffers^{1,2}*, Eithne J. Comerford^{1,2,5}*

¹Department of Musculoskeletal Biology I, Institute of Life Course and Medical Sciences, University of Liverpool, William Duncan Building, Liverpool, UK

²The MRC-Arthritis Research UK Centre for Integrated Research into Musculoskeletal Ageing (CIMA), Liverpool, UK

³Centre for Genomic Research, Institute of Integrative Biology, Biosciences Building, Crown Street, University of Liverpool, Liverpool L69 7ZB, UK

⁴Department of Orthopaedic Surgery, Maastricht University Medical Centre, 6202 AZ Maastricht, The Netherlands

⁵Institute of Veterinary and Ecological Sciences, Leahurst Campus, University of Liverpool, Neston, UK

*Correspondence to: Yalda Ashraf Kharaz

Tel: 0151 7956100 Email: Y. Ashraf-Kharaz@liverpool.ac.uk

Department of Musculoskeletal Biology I, Institute of Ageing and Chronic Disease, 6 West Derby Street, Liverpool, L7 8TX

* These authors have contributed equally to this manuscript.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24

25 Keywords: snoRNAs, microRNAs, anterior cruciate ligament, osteoarthritis and small
26 non-coding RNAs

27

28 **ABSTRACT**

29 The anterior cruciate ligaments are susceptible to degeneration, resulting in pain,
30 reduced mobility and development of the degenerative joint disease osteoarthritis.
31 There is currently a paucity of knowledge on how anterior cruciate ligament
32 degeneration and disease can lead to osteoarthritis. Small non-coding RNAs
33 (sncRNAs), such as microRNAs, and small nucleolar RNA, are important regulators
34 of gene expression. We aimed to identify sncRNA profiles of human anterior cruciate
35 ligaments to provide novel insights into their roles in osteoarthritis.

36 RNA was extracted from the anterior cruciate ligaments of non-osteoarthritic knee
37 joints (control) and end-stage osteoarthritis knee joints, used for small RNA
38 sequencing and significantly differentially expressed sncRNAs defined. Bioinformatic
39 analysis was undertaken on the differentially expressed miRNAs and their putative
40 target mRNAs to investigate pathways and biological processes affected.

41 Our analysis identified 184 sncRNA that were differentially expressed between control
42 ACLs derived from osteoarthritic joints with a false discovery adjusted p value<0.05;
43 68 small nucleolar RNAs, 26 small nuclear RNAs and 90 microRNAs. We identified
44 both novel and previously identified (miR-206, -101, -365 and -29b and -29c)
45 osteoarthritis-related microRNAs and other sncRNAs (including SNORD74,
46 SNORD114, SNORD72) differentially expressed in ligaments derived from
47 osteoarthritic joints. Significant cellular functions deduced by the differentially

expressed miRNAs included differentiation of muscle ($P < 0.001$), inflammation ($P < 1.42E-10$), proliferation of chondrocytes ($P < 0.03$), fibrosis ($P < 0.001$) and cell viability ($P < 0.03$). Putative mRNAs were associated with the canonical pathways 'Hepatic Fibrosis Signalling' ($P < 3.7E-32$), and 'Osteoarthritis' ($P < 2.2E-23$). Biological processes included apoptosis ($P < 1.7E-85$), fibrosis ($P < 1.2E-79$), inflammation ($P < 3.4E-88$), necrosis ($P < 7.2E-88$) and angiogenesis ($P < 5.7E-101$).

SnRNAs are important regulators of anterior cruciate disease during osteoarthritis and may be used as therapeutic targets to prevent and manage anterior cruciate ligament disease and the resultant osteoarthritis.

INTRODUCTION

Ligaments are resilient connective tissues essential for bone-to-bone connections within joints [1]. The anterior cruciate ligament (ACL) is the most commonly damaged ligament [2] with an incidence of approximately 68.6 ACL ruptures per 100,000 people [3] resulting in considerable social and economic costs [4, 5]. In the USA alone, there are approximately 100,000-175,000 ACLs surgeries per year, with cost exceeding of 2 billion dollars [6, 7]. ACL injuries can also lead to significant functional impairment in athletes, muscle atrophy and weakness, joint instability, meniscal lesions, and are associated with development of osteoarthritis (OA) [8, 9]. In the case of the knee joint, more than 50% of ACL injury patients eventually develop OA with the degree and progression of disease being accelerated in these cases [10, 11]. Reports demonstrate that there is an association between ACL degeneration and subsequent knee OA, suggesting the importance of ACL degradation in OA pathogenesis [12].

72

73 There is currently substantial interest in the area of epigenetic regulation in ageing,
 74 disease, and repair mechanisms in musculoskeletal tissues such as muscle [13, 14],
 75 cartilage [15, 16], tendon [17, 18] and ligament [19, 20]. Epigenetics is the study of
 76 changes in gene expression that do not derive from changes to the genetic code itself
 77 [21]. Insufficient exploration of the epigenetic changes in diseased ACL has been
 78 undertaken. One class of epigenetic molecules are small non-coding RNAs (sncRNAs)
 79 which include microRNAs (miRNAs or miRs), small nucleolar RNAs (snoRNAs) and
 80 small nuclear RNAs (snRNAs) These are functional RNA molecules that are
 81 transcribed from DNA but do not translate into proteins and are emerging as important
 82 regulators of gene expression before and after protein transcription. Their aberrant
 83 expression profiles in musculoskeletal conditions such as ACL injury are expected to
 84 be associated with cellular dysfunction and disease development [22]. We have
 85 previously identified changes in the sncRNA profiles in ageing and OA human and
 86 equine cartilage [16, 23, 24], ageing human and equine tendon [25, 26] and ageing
 87 and OA murine joints and serum [27]. Identifying sncRNAs associated with ACL
 88 degradation and comprehending their role in OA could have an enormous impact on
 89 the understanding of its pathogenesis and future management.

90

91 To date, little is known about the sncRNA changes in diseased ACL. We hypothesise
 92 that sncRNA expression is altered in ACLs derived from OA joints and that their
 93 identification may elucidate the underlying mechanisms of ACL degeneration. This
 94 information could then provide potential diagnostic markers and enable future
 95 therapeutic targets to treat ACL degeneration, facilitating prompt positive intervention
 96 in the associated development of OA.

97

98 **MATERIALS AND METHODS**

99 All reagents were from ThermoFisher Scientific, unless otherwise stated.

100 **Sample collection**

101 ACLs from non-OA, apparently healthy knee joints (control) (n=4) were obtained from
 102 a commercial biobank (Articular Engineering). Ethical approval for the purchase
 103 human ACL tissue was granted by the Central University Research Ethics Committee
 104 C, University of Liverpool (RETH4721). Diseased OA ACLs were obtained from the
 105 knee joints of patients undergoing total knee arthroplasty for end-stage OA treatment
 106 (n=4). Fully informed patient consent was given for the use of these samples under
 107 the institutional ethical approval (Maastricht University Medical Centre approval IDs:
 108 MUMC 2017-0183). Samples were collected in RNAlater and stored at -80°C until
 109 used.

110

111 **RNA extraction**

112 RNA was extracted from ACL tissues once pulverised into a powder with a
 113 dismembranator (Mikro-S, Sartorius, Melsungen, Germany) under liquid nitrogen.
 114 Total RNA was extracted using the miRNeasy kit (Qiagen, Manchester, UK) according
 115 to the manufacturer's instructions. The RNA samples were quantified using a
 116 Nanodrop spectrophotometer (NanoDrop Technologies, Wilmington, USA). The
 117 integrity of the RNA was assessed on the Agilent 2100 Bioanalyzer (Agilent, Stockport,
 118 UK) using an RNA Pico chip (Agilent, Stockport, UK).

119

120 **Small RNA-Sequencing analysis: cDNA library preparation and sequencing**

121 1000ng RNA per sample was submitted for library preparation using NEBNext® Small
122 RNA Library Prep Set for Illumina (New England Biosciences (NEB), Ipswich, USA)
123 but with the addition of a Cap-Clip™ Acid Pyrophosphatase (Cell script, Madison,
124 USA) step to remove any 5' cap structures on some snoRNAs [27] and size selected
125 using a range 120-300bp (including adapters). This enabled both miRNAs and
126 snoRNAs to be identified using a non-biased approach. The pooled libraries were
127 sequenced on an Illumina HiSeq4000 platform with version 1 chemistry to generate 2
128 x 150 bp paired-end reads.

129

130 **Data processing**

131 Sequence data were processed through a number of steps to obtain non-coding RNA
132 expression values including; basecalling and de-multiplexing of indexed reads using
133 CASAVA version 1.8.2; adapter and quality trimming using Cutadapt version 1.2.1 [28]
134 and Sickle version 1.200 to obtain fastq files of trimmed reads; aligning reads to human
135 genome reference sequences (release 95) from Ensembl using Tophat version 2.0.10
136 [29] with option “-g 1”; counting aligned reads using HTSeq-count [30] against the
137 features defined in human genome GTF file (release 95). The features whose biotype
138 belonged to the gene categories such as miRNA, snoRNA, and snRNA were
139 extracted.

140 Differential expression (DE) analysis was performed in R using package DESeq2 [31].

141 The processes and technical details of the analysis include; assessing data variation

142 and detecting outlier samples through comparing variations of within and between

sample groups using principle component analysis (PCA) and correlation analysis; handling library size variation using DESeq2 default method; formulating data variation using negative binomial distributions; modelling data using a generalised linear model; computing log fold change (logFC) values for control versus OA ACLs based on model fitting results through contrast fitting approach, evaluating the significance of estimated logFC values by Wald test; adjusting the effects of multiple tests using false discovery rate (FDR) [32] approach to obtain FDR adjusted P-values.

Pathway analysis of differentially expressed miRNAs and their predicted targets

Potential biological associations of the DE miRNAs in OA ACL were identified using Ingenuity Pathway Analysis (IPA) (IPA, Qiagen Redwood City, USA) 'Core Analysis'. Additionally in order to identify putative miRNA targets, bioinformatic analysis was performed by uploading DE miRNA data into the MicroRNA Target Filter module within IPA. This identifies experimentally validated miRNA-mRNA interactions from TarBase, miRecords, and the peer-reviewed biomedical literature, as well as predicted miRNA-mRNA interactions from TargetScan. We applied a conservative filter at this point, using only experimentally validated and highly conserved predicted mRNA targets for each miRNA. Targets were also filtered on the cells fibroblasts and mesenchymal stem cells (as these were closest to potential cell types within ligament). 'Core Analysis' was then performed in IPA on the filtered mRNA target genes and their associated miRNAs. For each core analysis canonical pathways, novel networks, diseases and functions, and common upstream regulators were queried.

Additionally TOPP Gene [33] was used for overrepresentation analysis of the mRNA targets from Target Filter using Fisher's Exact test with FDR correction. This tests whether the input mRNAs associate significantly with specific pathways and generates a list of biological process gene ontology (GO) terms. Terms with FDR adjusted $P < 0.05$ were summarised using REViGO [34] with allowed similarity of 0.4 and visualised using Cytoscape [35].

Statistical analysis

The heatmap, volcano and principle component analysis (PCA) plots were made using MetaboAnalyst 3.5 (<http://www.metaboanalyst.ca>) which uses the R package of statistical computing software [36].

RESULTS

Sample assessment

The ages of the control group (age, mean $\pm$ standard deviation (48 ± 2.16)) and ACLs derived from OA joints (74.7 ± 5.42) were significantly different ($p < 0.05$) (Supplementary Figure 1). Summary of all donors' information is provided in Supplementary Table 1.

Analysis of small RNA sequencing data

We identified a total 590 miRNAs, 226 snoRNAs and 100 small nuclear (snRNAs) in the samples (with greater than 10 counts per million (CPM) in each samples). There were 184 differentially expressed sncRNAs identified ($FDR < 0.05$) and at least 10 CPM in each sample. The categories of RNA identified are in Figure 1A and included

miRNAs, snoRNAs and small nuclear RNAs (snRNAs). PCA revealed that the ACLs derived from non-OA joints (control) were clustered together and could be clearly separated from the ACLs derived from OA knee joints (Figure 1B).

Of the 184 snRNAs there were 68 DE snoRNAs (64 reduced in OA and 4 increased in OA), 26 DE snRNAs (24 reduced in OA and 2 increased in OA) and 90 DE miRNAs (43 reduced in OA and 47 increased in OA) (FDR<0.05 and greater than 10 CPM in all samples) (Figure 1C, Supplementary Table 2). The most DE miRNAs are in Table 1, with snRNA and snoRNAs in Table 2. We further generated a heatmap of the DE sncRNAs for miRNAs (Figure 1D) and snRNAs and snoRNAs (Supplementary Figure 2).

Pathway analysis of differentially expressed miRNAs

To explore potential biological associations of the 90 DE miRNAs in ACLs derived from OA knee joints we undertook an IPA 'Core Analysis'. Network-eligible molecules were overlaid onto molecular networks based on information from Ingenuity Pathway Knowledge Database. Networks were then generated based on connectivity. Interesting features were determined from the gene networks inferred. Significant cellular functions deduced by the DE miRNAs included differentiation of muscle (P<0.001), inflammation (P<1.42E-10), proliferation of chondrocytes (P<0.03), fibrosis (P<0.001) and cell viability (P<0.03) (Figure 2A). The top scoring network identified was 'Organismal Injury and Abnormalities' (score 43) and included OA-related miRNAs such as miR-206, miR-101, let-7f, miR-455, miR-29b and miR-29c (Figure 2B).

Pathway analysis on target mRNA genes of the differentially expressed miRNAs

Next, we undertook analysis to determine the mRNA targets of the DE miRNAs. 90 miRNAs that were DE in ACLs derived from OA knee joints compared to controls were initially input into MicroRNA Target Filter. Once a conservative filter was applied (only miRNAs with experimental or highly predicted targets), 529 mRNAs were putative targets (Supplementary Table 3). These mRNAs were then input into IPA core analysis and all results summarised in Supplementary Table 3. The top canonical pathways for target mRNAs of DE miRNAs in OA ACL are in Table 3. Two of the most significant of which were the osteoarthritis pathway ($P < 2.3 \times 10^{-23}$) and hepatic fibrosis ($P < 3.1 \times 10^{-32}$) (Figure 3). The most significant upstream regulators of these mRNAs included tumour necrosis factor ($P < 1.3 \times 10^{-101}$) and transforming growth factor β (TGF β) ($P < 8.5 \times 10^{-83}$) (Table 4). Upstream regulators represent molecules that may be responsible for the putative mRNAs in our dataset and cover the gamut of molecule types found in the literature, from transcription factors, to cytokines, chemicals and drugs. The most significant diseases and biological functions identified are shown in Table 5. The top networks identified are in Supplementary Table 3. The network 'cellular development, movement and genes expression' (score 41) (Figure 4A) was overlaid with significant biological processes including apoptosis ($P < 1.7 \times 10^{-85}$), fibrosis ($P < 1.2 \times 10^{-79}$), inflammation ($P < 3.4 \times 10^{-88}$), and necrosis ($P < 7.2 \times 10^{-88}$). The network 'inflammatory disease' (score 35) (Figure 4B) shows pertinent significant biological processes including organisation of collagen fibrils ($P < 3.7 \times 10^{-7}$), fibrosis ($P < 2.6 \times 10^{-14}$), rheumatoid arthritis ($P < 3.6 \times 10^{-6}$), angiogenesis ($P < 8.9 \times 10^{-9}$), differentiation of bone ($P < 5 \times 10^{-6}$), inflammation of the joint ($P < 8.8 \times 10^{-7}$) and cartilage development (1.5×10^{-7}).

To obtain an overview of pathways that the putative target mRNAs were involved in the mRNAs derived from IPA were also input into the gene ontology (GO) tool TOPP Gene and the biological processes summarised in REViGO and visualised using Cytoscape (Figure 5 and Supplementary Table 4).

DISCUSSION

The global prevalence of knee OA is currently 5% and is projected to rise with an increase in the ageing population [37]. Reports propose that there is an association between ACL degeneration and subsequent knee OA, suggesting the importance of ACL degradation and regeneration molecular mechanisms in OA pathogenesis [38]. There is also a strong correlation between ACL degeneration and subsequent knee OA [12]. One potential mechanism capable of regulating global alterations to a particular tissue is modification of sncRNA expression. To begin to elucidate the role that they play in the global changes observed in the ACL during OA and understand further the potential role of the ACL in arthritis, we undertook a non-biased approach small RNA sequencing of ACLs from OA knee joints and compared these to our control samples derived from non-OA knee joints. Whilst a study previously demonstrated DE miRNAs in ACL [20], this is the first time that, to our knowledge, small RNA sequencing has been used to interrogate both snoRNAs and miRNAs in an unbiased manner and we identified unique OA dependant signatures.

There were 68 snoRNAs, 26 snRNAs and 90 miRNAs significantly different in ACLs derived from OA knee joints and the OA status of the donor accounted for the principal variability in the data. Additional bioinformatics was performed, to analyse the

biological processes and pathways affected by the differentially expressed miRNAs and in addition, the putative mRNA targets of the differentially expressed miRNAs, enhancing our understanding of the roles of the dysregulated miRNAs in OA pathogenesis.

Several of DE miRNAs found in this study, including miR-29b, miR -335, let-7f, miR-424, and miR-941 correlate to previously altered miRNAs in a study comparing ruptured ACLs to diseased OA ACLs [20]. These miRNAs were found to be correlated with cartilage development and remodelling, extracellular matrix homeostasis and inflammatory response [20]. We have found other miRNAs associated with OA including miR-206, miR-101, miR365, miR-29b and miR-29c, whose expression altered in ACLs derived from OA joints [39-41]. Pathways identified by the DE miRNAs with known functions in OA in other tissues included inflammation [42], proliferation of chondrocytes [43], and fibrosis [44]. Canonical pathways identified have roles in OA pathogenesis including senescence [45], fibrosis, TGF β signalling [46], retinoic acid binding protein (RAR) activation [47] and peroxisome proliferator-activated receptor/retinoid X receptor (PPAR/RXR) activation [48, 49].

To address the roles of miRNAs in diseased OA ACLs, their mRNA target genes should also be taken into consideration. Therefore, in order to determine potential mRNA targets of the DE miRNAs we used Target Filter in IPA to identify predicted mRNA targets. We used conservative filters for the mRNAs identified by only choosing highly conserved predicted mRNA targets for each miRNA and by choosing relevant cell types to ACL tissue. We then undertook GO analysis and visualisation of the significant biological processes effected with online tools. Using ToppGene, Revigo

and Cytoscape for visualisation, we showed an overview of the essential biological processes these mRNA target genes were involved in, including extracellular matrix organisation, epigenetic regulation, cell signalling, cell growth and proliferation. In IPA, additional functions affected by these genes, known to have a role in OA pathogenesis and therefore with a potential role in OA ACLs were highlighted including apoptosis [50], fibrosis [44], inflammation of the joint [42], necrosis [51], organisation of collagen fibrils [12], angiogenesis [52], differentiation of bone [53] and cartilage development [54]. Canonical pathway analysis was also performed. We found that many pathways enriched by the putative target genes were essential for OA pathogenesis, including the 'osteoarthritis pathway'. The significant mRNA targets in this pathway included those involved in inflammation (TNF, IL1, IL8), Wnt signalling (WNT3A, Frizzled, TCF/LEF), TGF β and SMAD signalling (TGF β R2, SMAD1, -4, -5, -8), hypoxia (HIF1 α), and mammalian target of rapamycin signalling (MTOR). Additionally downstream targets of these signalling pathways with known roles in OA pathogenesis were identified and included matrix metalloproteinase-3 [55], tissue inhibitor of metalloproteinase-3 [56], and collagen X α 1 [57]. These findings indicate the potential importance of these pathways in ACL degeneration associated with OA. Hepatic fibrosis was the most significant canonical pathway identified from the putative mRNAs together with the DE miRNAs in our study. Synovial fibrosis is often found in OA [44] and fibrosis has previously been described in OA joints following ACL injury [58]. Furthermore TGF β , one of the most significant upstream regulator in our mRNA target gene analysis, is the master regulator of fibrosis [57]. Many TGF β -related genes including TGF β 2, TGF β 3, TGF β R1, TGF β R2 and TGF β R3 were predicted targets of the DE miRNAs including miR-98-5p, miR-101-3p, miR-128-5p, miR-136-3p, miR-17-5p; strongly implicating it in the fibrosis evident in the diseased ACLs in OA.

314

315 Another class of snRNAs, snoRNAs, were altered in the OA ACLs in our study. This
316 conserved class of non-coding RNAs are principally characterised as guiding site-
317 specific post-transcriptional modifications in ribosomal RNA [59]. Furthermore
318 snoRNAs can modify and/or interact with additional classes of RNAs including other
319 snoRNAs, transfer RNAs and mRNAs [60]. A reliable modification site has been
320 assigned to 83% of the canonical snoRNAs, with 76 snoRNAs described as orphan,
321 meaning they act in an unknown or unique manner [61]. Novel functions reported for
322 snoRNAs including the modulation of alternative splicing [62], involvement in stress
323 response pathways, [63] and the modulation of mRNA 3'end processing [64]. Like
324 miRNAs, snoRNAs are emerging as important regulators of cellular function and
325 disease development [65], in part due to their ability to fine-tune the ribosome to
326 accommodate changing requirements for protein production during development,
327 normal function and disease [66] .

328

329 We have previously identified a role for snoRNAs in cartilage ageing and OA [24] and
330 their potential use as biomarkers for OA [27]. Furthermore, others identified that the
331 snoRNAs, SNORD38 and SNORD48, are significantly elevated in the serum of
332 patients developing cartilage damage a year following ACL injury and serum levels of
333 SNORD38 were greatly elevated in patients who develop cartilage damage after ACL
334 injury suggesting SNORD38 as a serum biomarker for early cartilage damage [67]

335

336 Interestingly, we found an increase in SNORD113 and SNORD114 in diseased OA
337 ACLs. These snoRNAs are located in imprinted human loci and may play a role in the
338 evolution and/or mechanism of epigenetic imprinting [61]. They belong to the C/D box

class of snoRNAs and most of the members of the box C/D family direct site-specific 2'-O-methylation of substrate RNAs. However, SNORD113 and SNORD114 differ from C/D box snoRNAs in their tissue specific expression profiles (including in fibroblasts, osteoblasts and chondrocytes [61] and the lack of complementarity to any RNA. As a result, they are not predicted to guide to 2'-O-methylation but have novel, unknown roles [61]. Additionally SNORD113-1 functions as a tumour suppressor in hepatic cell carcinoma by reducing cell growth and inactivating the phosphorylation of ERK1/2 and SMAD2/3 in MAPK/ERK and TGF- β pathways [68]. We have previously identified that SNORD113-1 is also increased in OA human knee cartilage but reduced in ageing human knee cartilage, whilst SNORD114 increases in OA knee cartilage [24].

SNORD72 was increased in diseased OA ACLs. In hepatocellular carcinoma, the overexpression of SNORD72 was found to enhance cell proliferation, colony formation and invasion by stabilising Inhibitor of differentiation (ID) genes which are a basic helix-loop-helix (bHLH) transcription factors [69]. The ID family genes have been shown to play a role in cell proliferation and angiogenesis [70]. The lack of a DNA binding domain, results in inhibition of the binding of other transcription factors to DNA in a dominant negative fashion [71]. The expression of some members of this family in rheumatoid arthritis synovium suggests they may have a role in human inflammatory disease [72]. Whilst the downstream signalling of snoRNAs is principally unknown, snoRNAs regulate ribosome biogenesis [73]. However a subclass of orphans do not have complementary RNA sequences [74]. Mao Chet et al., found that ribosome biogenesis was not affected following SNORD72 overexpression implying it exerts functionality in other ways [69]. Therefore whilst some snoRNAs can regulate

the expression of RNAs [75], others can reduce the gene stability [74] or directly activate or suppress enzymes [76]. Together our snoRNA findings indicate that changes in ACL snoRNA expression could have important implications in knee OA through both canonical and non-canonical roles.

Our study has a number of limitations due to availability of human ACL tissue. There was also a mild imbalance between the sexes in the two groups with most of the OA derived ACLs coming from males but all the control group being sourced from females. In human tendon, we have previously demonstrated that males and females are transcriptionally different and gene expression in aged cells moves in opposite directions [26]. Ligament degeneration has also been demonstrated to be influenced by lower concentrations of sex hormones in young female athletes [77]. Macroscopic grading of tissues were not performed due to limited images of diseased OA ACL samples, however images of control samples demonstrated healthy knee joint cartilage with no signs of ACL degeneration. Finally, there were age discrepancies between the two groups and so we cannot discount an age effect on sncRNAs expression.

In conclusion, our study revealed alterations in a number of classes of snRNAs in ACL tissues derived from patients with knee OA compared to apparently healthy ACLs from non-OA joints. Our functional bioinformatic analyses suggests that the dysregulated miRNAs may regulate cartilage development and remodelling, collagen biosynthesis and degradation, ECM homeostasis and pathology by interacting with their targets. Uniquely we also demonstrate that snoRNAs may also have a role in ACL

degeneration. Collectively, our study provides novel insight into the ACL related
sncRNA dysregulation in patients with OA.

Competing interests

The authors declare no competing interests.

Acknowledgement

Mandy Peffers funded through a Wellcome Trust Intermediate Clinical Fellowship
(107471/Z/15/Z). This work was also supported by Institute of Ageing and Chronic
disease (Comerford) and by the MRC and Versus Arthritis as part of the Medical
Research Council Versus Arthritis Centre for Integrated Research into
Musculoskeletal Ageing (CIMA) [MR/R502182/1]. The MRC Versus Arthritis Centre for
Integrated Research into Musculoskeletal Ageing is a collaboration between the
Universities of Liverpool, Sheffield and Newcastle. The authors would like to
acknowledge, Dr Pieter Emans, Maastricht University Orthopaedic surgeon for
collating OA diseased samples.

Authors' contributions

MP, EC and YAK designed and coordinated the study. TW collected the samples.
YF processed the samples for small RNA sequencing. MP and YA conducted the
statistical analysis and drafted the manuscript. All authors revised the draft critically
read and approved the final submitted manuscript.

References

1. Rumian, A.P., A.L. Wallace, and H.L. Birch, *Tendons and ligaments are anatomically distinct but overlap in molecular and morphological features—a comparative study in an ovine model*. Journal of orthopaedic research, 2007. **25**(4): p. 458-464.
2. Woo, S.L.Y., et al., *Injury and Repair of Ligaments and Tendons*. Annual Review of Biomedical Engineering, 2000. **2**(1): p. 83-118.
3. Gianotti, S.M., et al., *Incidence of anterior cruciate ligament injury and other knee ligament injuries: A national population-based study*. Journal of Science and Medicine in Sport, 2009. **12**(6): p. 622-627.
4. Robling, M.R., et al., *Time to talk? Patient experiences of waiting for clinical management of knee injuries*. Quality and Safety in Health Care, 2009. **18**(2): p. 141-146.
5. Cumps, E., et al., *Injury rate and socioeconomic costs resulting from sports injuries in Flanders: data derived from sports insurance statistics 2003*. British journal of sports medicine, 2008. **42**(9): p. 767-772.
6. Ali, N. and G. Rouhi, *Barriers to predicting the mechanisms and risk factors of non-contact anterior cruciate ligament injury*. The open biomedical engineering journal, 2010. **4**: p. 178.
7. Griffin, L.Y., et al., *Noncontact anterior cruciate ligament injuries: risk factors and prevention strategies*. JAAOS-Journal of the American Academy of Orthopaedic Surgeons, 2000. **8**(3): p. 141-150.
8. Kiapour, A. and M. Murray, *Basic science of anterior cruciate ligament injury and repair*. Bone and Joint Research, 2014. **3**(2): p. 20-31.
9. Wurtzel, C.N., et al., *Pharmacological inhibition of myostatin protects against skeletal muscle atrophy and weakness after anterior cruciate ligament tear*. Journal of Orthopaedic Research, 2017.
10. Driban, J.B., et al., *Association of knee injuries with accelerated knee osteoarthritis progression: data from the Osteoarthritis Initiative*. Arthritis care & research, 2014. **66**(11): p. 1673-1679.
11. Barenus, B., et al., *Increased risk of osteoarthritis after anterior cruciate ligament reconstruction: a 14-year follow-up study of a randomized controlled trial*. The American journal of sports medicine, 2014. **42**(5): p. 1049-1057.
12. Hasegawa, A., et al., *Anterior cruciate ligament changes in the human knee joint in aging and osteoarthritis*. Arthritis & Rheumatism, 2012. **64**(3): p. 696-704.
13. Soriano-Arroquia, A., et al., *The functional consequences of age-related changes in microRNA expression in skeletal muscle*. Biogerontology, 2016. **17**(3): p. 641-654.

14. Goljanek-Whysall, K., D. Sweetman, and A.E. Münsterberg, *microRNAs in skeletal muscle differentiation and disease*. Clinical science, 2012. **123**(11): p. 611-625.
15. Peffers, M., et al., *BIG tasks for small RNAs; a new class of rnas in the pathogenesis of osteoarthritis*. Osteoarthritis and Cartilage, 2016. **24**: p. S372.
16. Balaskas, P., et al., *MicroRNA Profiling in Cartilage Ageing*. International journal of genomics, 2017. **2017**.
17. Millar, N.L., et al., *MicroRNA29a regulates IL-33-mediated tissue remodelling in tendon disease*. Nature communications, 2015. **6**: p. 6774.
18. Watts, A.E., et al., *MicroRNA29a treatment improves early tendon injury*. Molecular Therapy, 2017. **25**(10): p. 2415-2426.
19. Xu, C., et al., *Integrated microRNA-mRNA analyses reveal OPLL specific microRNA regulatory network using high-throughput sequencing*. Scientific reports, 2016. **6**: p. 21580.
20. Li, B., et al., *Identification of differentially expressed microRNAs in knee anterior cruciate ligament tissues surgically removed from patients with osteoarthritis*. International journal of molecular medicine, 2017. **40**(4): p. 1105-1113.
21. Barter, M., C. Bui, and D. Young, *Epigenetic mechanisms in cartilage and osteoarthritis: DNA methylation, histone modifications and microRNAs*. Osteoarthritis and cartilage, 2012. **20**(5): p. 339-349.
22. Choudhuri, S., *Small noncoding RNAs: biogenesis, function, and emerging significance in toxicology*. J Biochem Mol Toxicol, 2010. **24**(3): p. 195-216.
23. Peffers, M.J., X. Liu, and P.D. Clegg, *Transcriptomic signatures in cartilage ageing*. Arthritis research & therapy, 2013. **15**(4): p. R98.
24. Peffers, M.J., et al., *snoRNA signatures in cartilage ageing and osteoarthritis*. Osteoarthritis and Cartilage, 2018. **26**: p. S164.
25. Peffers, M.J., et al., *Transcriptome analysis of ageing in uninjured human Achilles tendon*. Arthritis Res Ther, 2015. **17**: p. 33.
26. Pease, L.I., et al., *Cross platform analysis of transcriptomic data identifies ageing has distinct and opposite effects on tendon in males and females*. Scientific Reports, 2017. **7**(1): p. 14443.
27. Steinbusch, M.M., et al., *Serum snoRNAs as biomarkers for joint ageing and post traumatic osteoarthritis*. Scientific Reports, 2017. **7**: p. 43558.
28. Martin, M., *Cutadapt removes adapter sequences from high-throughput sequencing reads*. EMBnet. journal, 2011. **17**(1): p. 10-12.
29. Kim, D., et al., *TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions*. Genome biology, 2013. **14**(4): p. R36.

30. Anders, S., P.T. Pyl, and W. Huber, *HTSeq—a Python framework to work with high-throughput sequencing data*. Bioinformatics, 2015. **31**(2): p. 166-169.
31. Anders, S. and W. Huber, *Differential expression analysis for sequence count data* *Genome Biology*. 11: R106. doi: 10.1186/gb-2010-11-10-r106 View Article PubMed. 2010, NCBI.
32. Benjamini, Y. and Y. Hochberg, *Controlling the false discovery rate: a practical and powerful approach to multiple testing*. Journal of the Royal statistical society: series B (Methodological), 1995. **57**(1): p. 289-300.
33. Chen, J., et al., *ToppGene Suite for gene list enrichment analysis and candidate gene prioritization*. Nucleic acids research, 2009. **37**(suppl_2): p. W305-W311.
34. Supek, F., et al., *REVIGO summarizes and visualizes long lists of gene ontology terms*. PloS one, 2011. **6**(7): p. e21800.
35. Shannon, P., et al., *Cytoscape: a software environment for integrated models of biomolecular interaction networks*. Genome research, 2003. **13**(11): p. 2498-2504.
36. Xia, J., et al., *MetaboAnalyst: a web server for metabolomic data analysis and interpretation*. Nucleic acids research, 2009. **37**(suppl_2): p. W652-W660.
37. Hawker, G.A., *Osteoarthritis is a serious disease*. Clin Exp Rheumatol, 2019. **37**(120): p. S3-S6.
38. Friel, N.A. and C.R. Chu, *The role of ACL injury in the development of posttraumatic knee osteoarthritis*. Clinics in sports medicine, 2013. **32**(1): p. 1-12.
39. Peffers, M., P. Balaskas, and A. Smagul, *Osteoarthritis year in review 2017: genetics and epigenetics*. Osteoarthritis and cartilage, 2018. **26**(3): p. 304-311.
40. Malemud, C.J., *MicroRNAs and osteoarthritis*. Cells, 2018. **7**(8): p. 92.
41. Endisha, H., et al., *The complex landscape of microRNAs in articular cartilage: biology, pathology, and therapeutic targets*. JCI insight, 2018. **3**(17).
42. Lieberthal, J., N. Sambamurthy, and C.R. Scanzello, *Inflammation in joint injury and post-traumatic osteoarthritis*. Osteoarthritis and cartilage, 2015. **23**(11): p. 1825-1834.
43. Liu, Y., et al., *Exosomal KLF3-AS1 from hMSCs promoted cartilage repair and chondrocyte proliferation in osteoarthritis*. Biochemical Journal, 2018. **475**(22): p. 3629-3638.
44. Remst, D.F., E.N. Blaney Davidson, and P.M. van der Kraan, *Unravelling osteoarthritis-related synovial fibrosis: a step closer to solving joint stiffness*. Rheumatology, 2015. **54**(11): p. 1954-1963.

- 529 45. Jeon, O.H., et al., *Senescent cells and osteoarthritis: a painful connection*.
530 The Journal of clinical investigation, 2018. **128**(4): p. 1229-1237.
- 531 46. Davidson Blaney, E., P. van der Kraan, and W. van den Berg, *TGF-beta and*
532 *osteoarthritis*. Osteoarthritis Cartilage, 2007. **15**: p. 597-604.
- 533 47. Zisakis, A., et al., *Expression of Retinoic Acid Receptor (RAR) α Protein in the*
534 *Synovial Membrane from Patients with Osteoarthritis and Rheumatoid*
535 *Arthritis*. International journal of biomedical science: IJBS, 2007. **3**(1): p. 46.
- 536 48. Li, X.-F., et al., *Functional role of PPAR- γ on the proliferation and migration of*
537 *fibroblast-like synoviocytes in rheumatoid arthritis*. Scientific reports, 2017.
538 **7**(1): p. 1-13.
- 539 49. Yang, H., et al., *CRISPR/Cas9-mediated genome editing efficiently creates*
540 *specific mutations at multiple loci using one sgRNA in Brassica napus*.
541 Scientific reports, 2017. **7**(1): p. 1-13.
- 542 50. Heraud, F., A. Heraud, and M. Harmand, *Apoptosis in normal and*
543 *osteoarthritic human articular cartilage*. Annals of the rheumatic diseases,
544 2000. **59**(12): p. 959-965.
- 545 51. Li, H., C. Chen, and S. Chen, *Posttraumatic knee osteoarthritis following*
546 *anterior cruciate ligament injury: Potential biochemical mediators of*
547 *degenerative alteration and specific biochemical markers*. Biomedical reports,
548 2015. **3**(2): p. 147-151.
- 549 52. Ashraf, S. and D.A. Walsh, *Angiogenesis in osteoarthritis*. Current opinion in
550 rheumatology, 2008. **20**(5): p. 573-580.
- 551 53. Ripmeester, E.G., et al., *Recent insights into the contribution of the changing*
552 *hypertrophic chondrocyte phenotype in the development and progression of*
553 *osteoarthritis*. Frontiers in bioengineering and biotechnology, 2018. **6**: p. 18.
- 554 54. Goldring, M.B. and K.B. Marcu, *Epigenomic and microRNA-mediated*
555 *regulation in cartilage development, homeostasis, and osteoarthritis*. Trends
556 in molecular medicine, 2012. **18**(2): p. 109-118.
- 557 55. Burrage, P.S., K.S. Mix, and C.E. Brinckerhoff, *Matrix metalloproteinases: role*
558 *in arthritis*. Front Biosci, 2006. **11**(1): p. 529-543.
- 559 56. Sahebjam, S., R. Khokha, and J.S. Mort, *Increased collagen and aggrecan*
560 *degradation with age in the joints of Timp3^{-/-} mice*. Arthritis & Rheumatism,
561 2007. **56**(3): p. 905-909.
- 562 57. Zhong, L., et al., *Correlation between gene expression and osteoarthritis*
563 *progression in human*. International journal of molecular sciences, 2016.
564 **17**(7): p. 1126.
- 565 58. Douglas, M., J. Hutchison, and A. Sutherland, *Anterior cruciate ligament*
566 *integrity in osteoarthritis of the knee in patients undergoing total knee*
567 *replacement*. Journal of Orthopaedics and Traumatology, 2010. **11**(3): p. 149.

- 568 59. Dieci, G., M. Preti, and B. Montanini, *Eukaryotic snoRNAs: a paradigm for*
569 *gene expression flexibility*. Genomics, 2009. **94**(2): p. 83-88.
- 570 60. Kishore, S., et al., *Insights into snoRNA biogenesis and processing from PAR-*
571 *CLIP of snoRNA core proteins and small RNA sequencing*. Genome biology,
572 2013. **14**(5): p. R45.
- 573 61. Jorjani, H., et al., *An updated human snoRNAome*. Nucleic acids research,
574 2016. **44**(11): p. 5068-5082.
- 575 62. Khanna, A. and S. Stamm, *Regulation of alternative splicing by short non-*
576 *coding nuclear RNAs*. rNA Biology, 2010. **7**(4): p. 480-485.
- 577 63. Michel, C.I., et al., *Small nucleolar RNAs U32a, U33, and U35a are critical*
578 *mediators of metabolic stress*. Cell metabolism, 2011. **14**(1): p. 33-44.
- 579 64. Huang, C., et al., *A snoRNA modulates mRNA 3' end processing and*
580 *regulates the expression of a subset of mRNAs*. Nucleic acids research, 2017.
581 **45**(15): p. 8647-8660.
- 582 65. Stepanov, G.A., et al., *Regulatory role of small nucleolar RNAs in human*
583 *diseases*. BioMed research international, 2015. **2015**.
- 584 66. Montanaro, L., D. Treré, and M. Derenzini, *Nucleolus, ribosomes, and cancer*.
585 The American journal of pathology, 2008. **173**(2): p. 301-310.
- 586 67. Zhang, L., et al., *Serum non-coding RNAs as biomarkers for osteoarthritis*
587 *progression after ACL injury*. Osteoarthritis and cartilage, 2012. **20**(12): p.
588 1631-1637.
- 589 68. Xu, G., et al., *Small nucleolar RNA 113-1 suppresses tumorigenesis in*
590 *hepatocellular carcinoma*. Molecular cancer, 2014. **13**(1): p. 216.
- 591 69. Mao, L.-H., et al., *LncRNA-LALR1 upregulates small nucleolar RNA*
592 *SNORD72 to promote growth and invasion of hepatocellular carcinoma*. Aging
593 (Albany NY), 2020. **12**(5): p. 4527.
- 594 70. Lyden, D., et al., *Id1 and Id3 are required for neurogenesis, angiogenesis and*
595 *vascularization of tumour xenografts*. Nature, 1999. **401**(6754): p. 670-677.
- 596 71. Benezra, R., et al., *A Negative Regulator of Helix-Loop-Helix DNA Binding*
597 *Proteins: Control of Terminal Myogenic Differentiation*. Annals of the New
598 York Academy of Sciences, 1990. **599**(1): p. 1-11.
- 599 72. Edhayan, G., et al., *Inflammatory properties of inhibitor of DNA binding 1*
600 *secreted by synovial fibroblasts in rheumatoid arthritis*. Arthritis research &
601 therapy, 2016. **18**(1): p. 87.
- 602 73. Gong, J., et al., *A pan-cancer analysis of the expression and clinical*
603 *relevance of small nucleolar RNAs in human cancer*. Cell reports, 2017. **21**(7):
604 p. 1968-1981.
- 605 74. Sharma, E., et al., *Global mapping of human RNA-RNA interactions*.
606 Molecular cell, 2016. **62**(4): p. 618-626.

607 75. Xing, Y.-H., et al., *SLERT regulates DDX21 rings associated with Pol I*
608 *transcription*. Cell, 2017. **169**(4): p. 664-678. e16.

609 76. Siprashvili, Z., et al., *The noncoding RNAs SNORD50A and SNORD50B bind*
610 *K-Ras and are recurrently deleted in human cancer*. Nature genetics, 2016.
611 **48**(1): p. 53.

612 77. Stijak, L., et al., *The influence of sex hormones on anterior cruciate ligament*
613 *rupture: female study*. Knee Surgery, Sports Traumatology, Arthroscopy,
614 2015. **23**(9): p. 2742-2749.

615

616

617

Table 1. Differentially expressed miRs with the highest and lowest log2 fold-change when comparing from control versus diseased OA anterior cruciate ligament (ACL).

miR	Log2 change	fold- FDR adjusted p-values
Genes with increased expression in diseased OA ACL		
hsa-miR-5100	3.75	6.2E-07
hsa-miR-31-5p	3.14	6.9E-15
hsa-miR-129-5p	2.42	4.0E-03
hsa-miR-144-3p	2.41	3.5E-04
hsa-miR-486-5p	2.33	3.2E-04
hsa-miR-370-3p	2.32	1.4E-06
hsa-miR-543	2.20	6.3E-03
hsa-miR-4521	2.19	5.1E-04
hsa-miR-493-5p	2.17	6.7E-04
hsa-miR-411-3p	2.16	3.9E-03
Genes with reduced expression in control ACL		
hsa-miR-206	-6.13	1.9E-06
hsa-miR-12136	-4.35	3.3E-18
hsa-miR-3182	-3.20	3.8E-10
hsa-miR-101-5p	-2.22	9.6E-03
hsa-miR-338-3p	-2.08	1.5E-02
hsa-miR-335-5p	-2.03	7.3E-03
hsa-miR-190b-5p	-1.98	2.5E-03
hsa-miR-29c-3p	-1.89	1.1E-02
hsa-miR-103a-5p	-1.86	3.7E-06
hsa-miR-30b-5p	-1.81	1.7E-02

Table 2. Small-non coding RNAs (small nucleolar RNAs (snoRNAs) and small nuclear RNA (sncRNA) identified as differentially expressed between control and anterior cruciate ligaments (ACLs) derived from osteoarthritic joints.

Name	Family	Action	Log2 fold-change	FDR adjusted p-value	Higher
SNORD114	C/D BOX	Site-specific 2'-O-methylation	3.60	4.7E-07	OA ACL
SNORD113	C/D BOX	Site-specific 2'-O-methylation	2.85	9.8E-05	OA ACL
RNU6	Spliceosome	Complex of snRNA and protein subunits that removes introns from a transcribed pre-mRNA	2.85	4.8E-03	OA ACL
SNORD72	C/D BOX	Site-specific 2'-O-methylation	1.83	4.2E-02	OA ACL
RNVU1-19	Spliceosome	Complex of snRNA and protein subunits that removes introns from a transcribed pre-mRNA	1.58	4.8E-02	OA ACL
RNU7-19P	Spliceosome	Complex of snRNA and protein subunits that removes introns from a transcribed pre-mRNA	-7.61	4.0E-07	Control ACL
RNU4-59P	Spliceosome	Complex of snRNA and protein subunits that removes introns from a transcribed pre-mRNA	-4.90	1.4E-33	Control ACL
SNORA36B	H/ACA box	H/ACA family of pseudouridylation guide snoRNAs	-4.25	2.7E-06	Control ACL
SNORA53	H/ACA box	H/ACA family of pseudouridylation guide snoRNAs	-3.68	5.1E-15	Control ACL
SNORA73B	H/ACA box	H/ACA family of pseudouridylation guide snoRNAs	-3.61	3.9E-05	Control ACL

Table 3. Top canonical pathways for target mRNAs of differentially expressed miRNAs in diseased OA anterior cruciate ligaments (ACLs).

Name	p-value	Overlap
Hepatic Fibrosis Signalling Pathway	1.62E-33	15.8 %
Hepatic Fibrosis/Hepatic Stellate Cell Activation	3.06E-32	23.1 %
Cardiac Hypertrophy Signalling	1.28E-28	12.3 %
Colorectal Cancer Metastasis Signalling	1.97E-27	17.4 %
Role of Macrophages, Fibroblasts and Endothelial Cells	2.32E-27	15.4 %

Table 4. Top upstream regulators of differentially expressed miRNAs in diseased OA anterior cruciate ligaments (ACLs).

Name	p-value
Tumour necrosis factor	1.31E-101
Transforming growth factor B1	8.50E-83
lipopolysaccharide	1.14E-81
Interleukin 1B	1.45E-77
tretinoin	9.26E-77

Figure legends

Figure 1. Overview of HiSeq transcriptomics data between control and diseased osteoarthritic (OA) human anterior cruciate ligament (ACL). A. Categories of RNAs identified in control and diseased OA ACL B) Principle component analysis revealed that small non-coding RNAs (sncRNA) between control and diseased ACL were distinctly grouped. C) Volcano plot demonstrate significant ($FDR < 0.05$) differentially expressed sncRNAs (red dots) with a fold-change of 1.4. D. Heatmap representation of the small non-coding RNA reads from control to OA ACL. Columns refer to the control and OA ACL samples and rows of miRNAs identified with their Ensembl identification. Heatmap was generated using log-transformed normalised read counts, normalisation was performed by EdgeR's trimmed mean of M values. The colour of each entry is determined by the number of reads, ranging from yellow (positive values) to red (negative values).

Figure 2. Ingenuity Pathway Analysis (IPA) derived functions of differentially expressed microRNAs in diseased osteoarthritic (OA) anterior cruciate ligament (ACL). A. IPA identified that cellular functions differentiation of muscle, inflammation, proliferation, cell viability and fibrosis were associated with the differentially expressed microRNAs. Figures are graphical representations between molecules identified in our data in their respective networks. Red nodes, upregulated in OA, and green nodes, downregulated gene expression in OA. Intensity of colour is related to higher fold-change. Legends to the main features in the networks are shown. Functions colour is dependent on whether it is predicted to be activated or inhibited. B. Top network identified with canonical pathways overlaid for fibrosis, senescence, TGF β signalling, RAR activation and PPAR/RXR activation.

Figure 3. Osteoarthritis pathway targeted by predicted mRNA. The canonical pathway for osteoarthritis signalling was highly ranked ($p = 2.33 \times 10^{-23}$) using target mRNAs identified in Ingenuity Pathway Analysis (IPA) Targets can from the differentially expressed miRNAs in diseased anterior cruciate ligaments (ACLs) derived from OA patients. The pathway was generated using IPA.

Figure 4. Top-scoring networks derived from the 529 putative mRNAs differentially expressed in anterior cruciate ligaments (ACLs) derived from osteoarthritic (OA) joints. Ingenuity pathway analysis (IPA) identified A. 'Cellular development, movement and genes expression' with a scores of 41. (B) 'Inflammatory disease, organismal injuries and abnormalities' with a score of 35 and within this network are molecules linked to their respective canonical pathways. Both are overlaid with pertinent significant biological functions contained in the gene sets. Figures are graphical representations between molecules identified in our data and predicted mRNA targets in their respective networks. Green nodes, downregulated in ACLs from OA joints; red nodes, upregulated gene expression in ACLs from OA joints. Intensity of colour is related to higher fold-change. Key to the main features in the networks is shown.

Figure 5. Gene ontology (GO) biological processes associated with dysregulated microRNAs targets were identified following TargetScan filter module using IPA. GO terms for biological process (FDR < 0.05) were summarized with ToppGene and visualised using REViGO and Cytoscape. Boxes represent the main clusters of biological processes that were significantly influenced by dysregulated microRNAs between control and diseased osteoarthritic (OA) anterior cruciate ligaments (ACLs).

Supplementary Figures and Tables:

Supplementary Figure 1. Age groups between control anterior cruciate ligament (ACL) samples and diseased OA ACL samples.

Supplementary Figure 2. Heatmap representation of the differentially expressed snoRNAs and sncRNAs small non-coding RNA reads from control to OA anterior cruciate ligament (ACL)

Supplementary Table 1. Donors' age, gender and ethnicity information.

Supplementary Table 2. Differentially expressed sncRNAs between control and OA anterior cruciate ligament (ACL) samples with FDR<0.05 and reads greater than 10 counts per million (CPM).

Supplementary Table 3. Ingenuity Pathway Analysis (IPA) of differentially expressed microRNAs target genes between control and OA anterior cruciate ligament (ACL) and IPA of mRNA core analysis of putative mRNAs targets

Supplementary Table 4. Gene ontology (GO) of the top biological processes gene ontology of putative mRNA targets between control and OA anterior cruciate ligament (ACL) summarised in REVIGO tool.

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.